**Patient Report** 

Ordering Physician:

Age:

Patient ID: Specimen ID: Sex:



### Ordered Items: CBC With Differential/Platelet; CEA; Prostate-Specific Ag; Venipuncture

DOB:

Date Collected: Date Received: Date Reported: Fasting:

# **CBC With Differential/Platelet**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
WBC 01	4.1		x10E3/uL	3.4-10.8
RBC 01	4.39		x10E6/uL	4.14-5.80
Hemoglobin 01	11.9		g/dL	13.0-17.7
Hematocrit <sup>01</sup>	37.4		%	37.5-51.0
MCV <sup>01</sup>	85		fL	79-97
MCH 01	27.1		pg	26.6-33.0
MCHC 01	31.8		g/dL	31.5-35.7
RDW <sup>01</sup>	13.3		%	11.6-15.4
Platelets 01	271		x10E3/uL	150-450
Neutrophils <sup>01</sup>	46		%	Not Estab.
Lymphs 01	42		%	Not Estab.
Monocytes 01	8		%	Not Estab.
Eos 01	3		%	Not Estab.
Basos <sup>01</sup>	1		%	Not Estab.
Neutrophils (Absolute) 01	1.9		x10E3/uL	1.4-7.0
Lymphs (Absolute) 01	1.7		x10E3/uL	0.7-3.1
Monocytes(Absolute) 01	0.3		x10E3/uL	0.1-0.9
Eos (Absolute) 01	0.1		x10E3/uL	0.0-0.4
Baso (Absolute) 01	0.0		x10E3/uL	0.0-0.2
Immature Granulocytes 01	0		%	Not Estab.
Immature Grans (Abs) 01	0.0		x10E3/uL	0.0-0.1

### **CEA**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval		
CEA 01	3.0		ng/mL	0.0-4.7		
		Nonsmokers	<3.9			
		Smokers	<5.6			
	Roche Diagnos	Roche Diagnostics Electrochemiluminescence Immunoassay				
	(ECLIA)					
	Values obtain	Values obtained with different assay methods or kits				
	cannot be use	d interchangeably. Results ca	nnot be			
	interpreted a	s absolute evidence of the pre	sence or			
	absence of ma	lignant disease.				

# **Prostate-Specific Ag**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval		
Prostate Specific Ag 01	1.5		ng/mL	0.0-4.0		
Roche ECLIA methodology.						
	According to the American Urological Association, Serum PSA should					
	decrease and remain at undetectable levels after radical					

labcorp Final Report Page 1 of 2 **Patient Report** 

Ordering Physician: Age: Sex:

DOB:



## **Prostate-Specific Ag (Cont.)**

prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

#### Disclaimer

Patient ID:

Specimen ID:

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

#### Icon Legend

Out of Reference Range Critical or Alert

**Performing Labs** 

**Patient Details** 

Phone. Date of Birth: Age:

Sex: Patient ID:

Alternate Patient ID:

Physician Details

**Request A Test** 7027 Mill Road Suite 201, BRECKSVILLE, OH, 44141

Phone: 888-732-2348 Physician ID:

NPI:

Specimen Details Specimen ID: Control ID:

Alternate Control Number:

Date Collected: Date Received: Date Entered: Date Reported:

Rte:

labcorp Final Report Page 2 of 2